Should I buy or sell InflaRx stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for InflaRx in the last twelve months. There are currently 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "strong buy" IFRX shares. View IFRX analyst ratings or view top-rated stocks .

What is InflaRx's stock price target for 2024?

2 analysts have issued 1 year price targets for InflaRx's shares. Their IFRX share price targets range from $8.00 to $19.00. On average, they expect the company's stock price to reach $13.50 in the next twelve months. This suggests a possible upside of 930.5% from the stock's current price. View analysts price targets for IFRX or view top-rated stocks among Wall Street analysts .

How have IFRX shares performed in 2024?

InflaRx's stock was trading at $1.63 at the start of the year. Since then, IFRX stock has decreased by 19.6% and is now trading at $1.31. View the best growth stocks for 2024 here .

Are investors shorting InflaRx?

InflaRx saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 389,100 shares, an increase of 22.9% from the March 15th total of 316,700 shares. Based on an average daily trading volume, of 234,200 shares, the days-to-cover ratio is currently 1.7 days. View InflaRx's Short Interest .

When is InflaRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our IFRX earnings forecast .

How were InflaRx's earnings last quarter?

InflaRx (NASDAQ:IFRX) announced its quarterly earnings results on Thursday, March, 21st. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by $0.10.

What ETF holds InflaRx's stock?

Amplify Treatments, Testing and Advancements ETF holds 15,278 shares of IFRX stock, representing 0.37% of its portfolio.

What other stocks do shareholders of InflaRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InflaRx investors own include Dynavax Technologies (DVAX) , Gilead Sciences (GILD) , ImmunoGen (IMGN) , Inovio Pharmaceuticals (INO) , AbbVie (ABBV) , OPKO Health (OPK) , Capricor Therapeutics (CAPR) , Citius Pharmaceuticals (CTXR) , Kadmon (KDMN) and Moderna (MRNA) .

When did InflaRx IPO?

InflaRx (IFRX) raised $100 million in an initial public offering (IPO) on Wednesday, November 8th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

How do I buy shares of InflaRx?

Shares of IFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:IFRX

InflaRx (IFRX) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free IFRX Stock Alerts

$1.31

+0.05 (+3.97%)

(As of 11:29 AM ET)

Compare

Today's Range: $1.27
▼
$1.36
50-Day Range: $1.26
▼
$1.79
52-Week Range: $1.14
▼
$5.20

Volume: 70,915 shs
Average Volume: 243,552 shs
Market Capitalization: $77.13 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.50

Get InflaRx alerts:

InflaRx MarketRank™ Stock Analysis

Analyst Rating: Strong Buy
3.50 Rating Score
Upside/Downside: 930.5% Upside
$13.50 Price Target
Short Interest: Healthy
0.66% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.00) to ($0.93) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.01 out of 5 stars

Medical Sector

445th out of 918 stocks

Pharmaceutical Preparations Industry

198th out of 423 stocks

3.8

Analyst's Opinion

Consensus Rating
InflaRx has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
InflaRx has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.66% of the outstanding shares of InflaRx have been sold short.
Short Interest Ratio / Days to Cover
InflaRx has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in InflaRx has recently increased by 22.86%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
InflaRx does not currently pay a dividend.
Dividend Growth
InflaRx does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IFRX.

2.7

News and Social Media Coverage

News Sentiment
InflaRx has a news sentiment score of 1.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for InflaRx this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for IFRX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added InflaRx to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, InflaRx insiders have not sold or bought any company stock.
Percentage Held by Insiders
16.30% of the stock of InflaRx is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
42.39% of the stock of InflaRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for InflaRx are expected to grow in the coming year, from ($1.00) to ($0.93) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of InflaRx is -1.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of InflaRx is -1.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
InflaRx has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Special FREE offer on stock hotsheets

These sheets tell you the exact day you should consider buying a stock… And the exact day you should consider selling it… All based on TEN YEARS of historic data and trends. For example, like January 6th through the 12th with Apple… It’s gone up every single year for the last decade. Or like May 26th through June 11th with LULU… Again - it’s gone up every single year for the last decade. Then there’s July 1st through the 21st with Walmart… What happened to WMT?

Click here and I’ll show you

About InflaRx Stock (NASDAQ:IFRX)

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

IFRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IFRX Stock News Headlines

March 22, 2024 | markets.businessinsider.com

Buy Rating Justified for InflaRx Despite Earnings Miss: Financial Stability and INF904’s Market Potential

March 21, 2024 | investorplace.com

IFRX Stock Earnings: InflaRx Misses EPS, Misses Revenue for Q4 2023

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

March 21, 2024 | globenewswire.com

InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans

March 20, 2024 | benzinga.com

6IFRX : Earnings Preview: InflaRx

March 19, 2024 | globenewswire.com

InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

March 6, 2024 | finance.yahoo.com

Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

February 22, 2024 | investing.com

InflaRx N.V. (IFRX)

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

February 22, 2024 | finance.yahoo.com

InflaRx Appoints Jan Medina as Head of Investor Relations

February 22, 2024 | globenewswire.com

InflaRx Appoints Jan Medina as Head of Investor Relations

February 17, 2024 | finance.yahoo.com

IFRX Apr 2024 2.500 call

January 25, 2024 | markets.businessinsider.com

Buy Recommendation for InflaRx Amidst Strategic Initiatives and Promising Clinical Advances

January 25, 2024 | finanznachrichten.de

InflaRx N.V.: InflaRx Announces Initiation of its Commitment Program for GOHIBIC(vilobelimab) to Help Broaden Access for Eligible Patients

January 25, 2024 | finance.yahoo.com

InflaRx N.V.'s (NASDAQ:IFRX) top owners are individual investors with 55% stake, while 23% is held by institutions

January 25, 2024 | finance.yahoo.com

InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients

January 6, 2024 | markets.businessinsider.com

InflaRx’s Promising INF904 Phase 1 Results Prompt Buy Rating

January 4, 2024 | finanznachrichten.de

InflaRx N.V.: InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904

January 4, 2024 | markets.businessinsider.com

InflaRx's MAD Part Phase 1 Trial For INF904 Reports Positive Results

January 4, 2024 | finance.yahoo.com

InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904

December 1, 2023 | finance.yahoo.com

Here's Why InflaRx N.V. (IFRX) Looks Ripe for Bottom Fishing

November 28, 2023 | finance.yahoo.com

After Plunging -17.65% in 4 Weeks, Here's Why the Trend Might Reverse for InflaRx N.V. (IFRX)

November 20, 2023 | morningstar.com

InflaRx NV IFRX

November 7, 2023 | markets.businessinsider.com

Buy Rating for InflaRx: Potential Breakthrough PG Treatment and Promising Revenue Forecasts

November 6, 2023 | finance.yahoo.com

InflaRx N.V. (IFRX) Loses -47.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

November 6, 2023 | finance.yahoo.com

InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

November 3, 2023 | msn.com

IFRX, LIXT and IOAC are among pre market gainers

See More Headlines

Receive IFRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InflaRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:IFRX
CUSIP: N/A
CIK: 1708688
Web: www.inflarx.de
Phone: 493641508180
Fax: 49-36-4150-8181
Employees: 62
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $13.50
High Stock Price Target: $19.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +971.4%
Consensus Rating: Strong Buy
Rating Score (0-4): 3.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.86)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-46,180,000.00
Net Margins: N/A
Pretax Margin: -67,630.59%
Return on Equity: -40.10%
Return on Assets: -36.24%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.50
Quick Ratio: 5.82

Sales & Book Value

Annual Sales: $70,000.00
Price / Sales: 1,059.84
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.89 per share
Price / Book: 0.67

Miscellaneous

Outstanding Shares: 58,880,000
Free Float: 49,285,000
Market Cap: $74.19 million
Optionable: Optionable
Beta: 1.27

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Niels C. Riedemann M.D. (Age 51)
Ph.D., Co-Founder, CEO & Executive Director
Prof. Renfeng Guo M.D. (Age 54)
Co-Founder, Chief Scientific Officer & Executive Director
Dr. Thomas Taapken Ph.D. (Age 59)
Chief Financial Officer
Ms. Derval O'Carroll (Age 58)
Senior VP and Global Head of Regulatory Affairs & Compliance
Dr. Camilla Chong M.D. (Age 58)
Chief Medical Officer
Mr. Jan Medina CFA
Head of Investor Relations & VP
Mr. Christian Schmid
VP and Head of Legal Affairs & General Counsel
Ms. Nicole Bertsch
Senior Director & Head of Human Resources
Dr. Maria Habel PH.D. (Age 42)
VP, Head of Preclinical R&D and QC
Dr. Bruce P. Burnett Ph.D.
VP & Head of Medical Affairs

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

IFRX Stock Analysis - Frequently Asked Questions

Should I buy or sell InflaRx stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for InflaRx in the last twelve months. There are currently 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "strong buy" IFRX shares.
View IFRX analyst ratings or view top-rated stocks.
What is InflaRx's stock price target for 2024?: 2 analysts have issued 1 year price targets for InflaRx's shares. Their IFRX share price targets range from $8.00 to $19.00. On average, they expect the company's stock price to reach $13.50 in the next twelve months. This suggests a possible upside of 930.5% from the stock's current price.
View analysts price targets for IFRX or view top-rated stocks among Wall Street analysts.
How have IFRX shares performed in 2024?: InflaRx's stock was trading at $1.63 at the start of the year. Since then, IFRX stock has decreased by 19.6% and is now trading at $1.31.
View the best growth stocks for 2024 here.
Are investors shorting InflaRx?: InflaRx saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 389,100 shares, an increase of 22.9% from the March 15th total of 316,700 shares. Based on an average daily trading volume, of 234,200 shares, the days-to-cover ratio is currently 1.7 days.
View InflaRx's Short Interest.
When is InflaRx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our IFRX earnings forecast.
How were InflaRx's earnings last quarter?: InflaRx (NASDAQ:IFRX) announced its quarterly earnings results on Thursday, March, 21st. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by $0.10.

What ETF holds InflaRx's stock?: Amplify Treatments, Testing and Advancements ETF holds 15,278 shares of IFRX stock, representing 0.37% of its portfolio.
What other stocks do shareholders of InflaRx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other InflaRx investors own include Dynavax Technologies (DVAX), Gilead Sciences (GILD), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), AbbVie (ABBV), OPKO Health (OPK), Capricor Therapeutics (CAPR), Citius Pharmaceuticals (CTXR), Kadmon (KDMN) and Moderna (MRNA).
When did InflaRx IPO?: InflaRx (IFRX) raised $100 million in an initial public offering (IPO) on Wednesday, November 8th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.
How do I buy shares of InflaRx?: Shares of IFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IFRX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial